In the past few years, several chimeric antigen receptor T (CAR-T) cells therapies have been explored to treat AML, including CD33, CD123, FLT3, and CLL-1 CAR-Ts (5–8). The gene discussed is FLT3; the disease is acute myeloid leukemia.